## Accepted Manuscript

New treatments to reach functional cure: Virological approaches

David Durantel

PII: S1521-6918(17)30040-9

DOI: 10.1016/j.bpg.2017.05.002

Reference: YBEGA 1512

To appear in: Best Practice & Research Clinical Gastroenterology

Received Date: 6 April 2017

Accepted Date: 13 May 2017

Please cite this article as: Durantel D, New treatments to reach functional cure: Virological approaches, *Best Practice & Research Clinical Gastroenterology* (2017), doi: 10.1016/j.bpg.2017.05.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



|    | ACCEPTED MANUSCRIPT   |
|----|---|
| 1  | New treatments to reach functional cure: Virological approaches                     |
| 2  | David Durantel <sup>1,2,3</sup>   |
| 3  |   |
| 4  | 1. INSERM, U1052, Lyon, 69003, France;  |
| 5  | 2. Cancer Research Center of Lyon (CRCL), Lyon, 69008, France;                      |
| 6  | 3. University of Lyon, UCBL1, UMR_S1052, UCBL, 69008 Lyon, France;                  |
| 7  |   |
| 8  | Correspondence:   |
| 9  | Dr. David Durantel  |
| 10 | Centre de Recherche en Cancérologie de Lyon (CRCL), UMR INSERM U1052 - CNRS         |
| 11 | 5286, 151 cours Albert Thomas, 69424 Lyon Cedex 03, France ; Phone: + 33 4 72 68 19 |
| 12 | 70 ; Fax : +33 4 72 68 19 71 ; E-mail : <u>david.durantel@inserm.fr</u> .           |
| 13 |   |
| 14 | Manuscript information :  |
| 15 | Abstract: xxx words   |
| 16 | Electronic word count: xxx  |
| 17 | Number of table:  |
| 18 | Number of figures:  |
| 19 |   |
| 20 | Additional Footnotes:   |
| 21 | None  |
| 22 |   |
| 23 | Conflict of interest:   |
| 24 | DD received research grants from Hoffmann-La-Roche, Gilead Sciences, Novira         |
| 25 | Therapeutics, Janssen, and Assembly Biosciences.                                    |
| 26 |   |
| 27 | Key Words:  |
| 28 | Hepatitis B virus; viral targets; direct acting antiviral (DAA); HBV cure; cccDNA.  |
| 29 |   |

Download English Version:

## https://daneshyari.com/en/article/5654501

Download Persian Version:

https://daneshyari.com/article/5654501

Daneshyari.com